Actually, SHIP2 inhibitors represent new treatments for several diseases: SHIP2 inhibition has been reported to partially rescue memory deficits in transgenic mouse models of diabetes and AD (Soeda et al., 2010; Kam et al., 2016) and to prevent metastasis in breast cancer cells (Ghosh et al., 2018). This evidence concerns the gene INPPL1 and diabetes mellitus.